CONTACT US

Eclipse Bio’s Revolutionary m6A-eCLIP Kit and Services

  • Published August 18, 2021
  • by Eclipsebio

Share

Eclipse Bio’s m6A-eCLIP utilizes the enhanced crosslinking and immunoprecipitation approach to profile m6A RNA modification sites transcriptome-wide with single nucleotide resolution.

N6-methyladenosine (m6A) is the most prevalent epitranscriptomic RNA modification found in eukaryotes and has been shown to regulate many aspects of RNA biology including splicing, secondary & tertiary structure, nuclear export, localization, stability, and translation.

Let Eclipse Bio advance your research, click the link here to learn more.

Related articles

Uncategorized

10
26
21

Eclipse Bio’s RBP-eCLIP™ kit has enabled the discovery of Ago2 particles forming from Gαq activation

Eclipse Bio’s RBP-eCLIP™ kit was cited in a recent publication, enabling the discovery of Ago2 particles forming from Gαq activation. Explore Advanced RNA Genomics Solutions. Find the publication here.

read more

Uncategorized

10
21
21

Eclipse Bio’s m6A-eCLIP™ service has enabled the discovery of Mettl3 as a p53-interacting protein.

Eclipse Bio’s m6A-eCLIP™ service was cited in a recent publication, enabling the discovery of Mettl3 as a p53-interacting protein. Explore Smarter RNA Genomics Solutions. Find the publication here.

read more

Uncategorized

10
15
21

Eclipse Bio’s miR-eCLIP™ service has enabled the discovery of Tobramycin as a suppressing factor in lung inflammation

Eclipse Bio’s miR-eCLIP™ service was cited in a recent publication, enabling the discovery of Tobramycin as a suppressing factor in lung inflammation, and as a gene silencing mechanism reducing IL-8 secretion in CF-HBECSs. Find the publication here.

read more

Uncategorized

10
15
21

Win a Free Kit! Enter our Grant Proposal Competition

Don’t miss out on this opportunity to win one of our kits! Eclipse Bio will be conducting a grant proposal competition! To enter, follow the directions above, and fill out a quick questionnaire to describe how you would take advantage of our industry leading RNA genomic technologies. Our submission deadline has been extended to December […]

read more